Drug profile · INN
linvoseltamab-gcpt
LYNOZYFIC
linvoseltamab-gcpt (LYNOZYFIC) is an FDA-listed pharmaceutical active ingredient. Associated with Shanghai Antengene Corporation Limited. Route of administration: injection. Current US regulatory status: approved.
Drug details — linvoseltamab-gcpt
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 10
- Programs
- 14
- Data quality
- 0.89
Quick answer
linvoseltamab-gcpt (LYNOZYFIC) is an FDA-listed pharmaceutical active ingredient. Associated with Shanghai Antengene Corporation Limited. Route of administration: injection. Current US regulatory status: approved.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
Pipeline programs
Related patents
-
US 12076418
Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo
granted -
US 11623011
Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo
granted -
US 11052157
Enhanced loading of intact, bacterially derived vesicles with small molecule compounds
granted -
US 10647785
High concentration chitosan-nucleic acid polyplex compositions
granted -
US 10328159
Enhanced loading of intact, bacterially derived vesicles with small molecule compounds
granted -
US 9850323
High concentration chitosan-nucleic acid polyplex compositions
granted -
US 9623112
Dually derivatized chitosan nanoparticles and methods of making and using the same
granted -
US 8722646
High concentration chitosan-nucleic acid polyplex compositions
granted -
US 8431543
Chitosan based polymer conjugate and a method for producing the same
granted -
US 7335646
Compositions and methods for regulated protein expression in gut
granted
Frequently asked questions
What is linvoseltamab-gcpt?
linvoseltamab-gcpt (LYNOZYFIC) is an FDA-listed pharmaceutical active ingredient. Associated with Shanghai Antengene Corporation Limited. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for linvoseltamab-gcpt?
LYNOZYFIC is a marketed brand name for linvoseltamab-gcpt. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of linvoseltamab-gcpt?
linvoseltamab-gcpt has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.